Evrópusambandið - íslenska - EMA (European Medicines Agency)

teva pharma b.v. - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - sturtu - eftir að/asetýlsalisýlsýru mg er ætlað til að fyrirbyggja atherothrombotic atburðum í fullorðinn sjúklinga þegar þú tekur bæði eftir og asetýlsalisýlsýru (asa). eftir að/asetýlsalisýlsýru mg er fastur‑skammt samsetning lyf fyrir áframhaldandi meðferð í:ekki l hækkun bráð kransæðastíflu (óstöðug hálsbólgu eða ekki q‑bylgja kransæðastíflu) þar á meðal sjúklinga gangast undir stoðneti staðsetningar eftir stungið kransæðastíflu interventionst hækkun, bráð myndun stíflufleygs í læknisfræðilega sjúklingum rétt fyrir segaleysandi meðferð.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

sanofi-aventis groupe - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - blóðþurrðandi lyf - bráðri kransæðastíflu syndromemyocardial hjartaáfall.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

mylan pharmaceuticals limited - acetylsalicylic acid, clopidogrel hydrogen sulfate - acute coronary syndrome; myocardial infarction - blóðþurrðandi lyf - eftir að/asetýlsalisýlsýru mylan er ætlað fyrir efri fyrirbyggja atherothrombotic atburðum í fullorðinn sjúklinga þegar þú tekur bæði eftir og asetýlsalisýlsýru (asa). eftir að/asetýlsalisýlsýru mylan er fastur-skammt samsetning lyf fyrir áframhaldandi meðferð í:ekki l hækkun bráð kransæðastíflu (óstöðug hálsbólgu eða ekki q-bylgja kransæðastíflu) þar á meðal sjúklinga gangast undir stoðneti staðsetningar eftir stungið kransæðastíflu interventionst hækkun, bráð myndun stíflufleygs í læknisfræðilega sjúklingum rétt fyrir segaleysandi meðferð.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris aps - acidum acetylsalicylicum; coffeinum - freyðitafla - 500/50 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris aps - acidum acetylsalicylicum; coffeinum - freyðitafla - 500 mg/50 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris aps - coffeinum; acidum acetylsalicylicum - freyðitafla - 50 mg/ 500 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

viatris aps - coffeinum; acidum acetylsalicylicum - freyðitafla - 500/50 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - blóðþurrðandi lyf - til að koma í veg fyrir segareki í bláæðum (vte) hjá fullorðnum sjúklingum sem gangast undir valhimnubólgu eða meðhöndlun á hné. meðferð djúpt æð blóðtappa (hjá sjúklingum sem fengu) og í lungum stíflu (pe), og koma í veg fyrir endurteknum hjá sjúklingum sem fengu pe í fullorðnir. (see section 4. 4 for haemodynamically unstable pe patients. meðferð djúpt æð blóðtappa (hjá sjúklingum sem fengu) og í lungum stíflu (pe), og koma í veg fyrir endurteknum hjá sjúklingum sem fengu pe í fullorðnir. (see section 4. 4 fyrir haemodynamically óstöðug pe sjúklingar). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. meðferð djúpt æð blóðtappa (hjá sjúklingum sem fengu) og í lungum stíflu (pe), og koma í veg fyrir endurteknum hjá sjúklingum sem fengu pe í fullorðnir. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 og 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. meðferð djúpt æð blóðtappa (hjá sjúklingum sem fengu) og í lungum stíflu (pe), og koma í veg fyrir endurteknum hjá sjúklingum sem fengu pe í fullorðnir. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - blóðþurrðandi lyf - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

bayer ag - rivaroxaban - arthroplasty, replacement; venous thromboembolism - blóðþurrðandi lyf - mælt, sam-gefið með asetýlsalisýlsýru (asa) einn eða með asa, plús eða eða tíclópidín, er ætlað til að fyrirbyggja atherothrombotic atburðum í fullorðinn sjúklinga eftir bráð kransæðastíflu (haft) með hækkun hjarta biomarkers. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. til að koma í veg fyrir segareki í bláæðum (vte) hjá fullorðnum sjúklingum sem gangast undir valhimnubólgu eða meðhöndlun á hné. meðferð djúpt æð blóðtappa (hjá sjúklingum sem fengu) og í lungum stíflu (pe), og koma í veg fyrir endurteknum hjá sjúklingum sem fengu pe í fullorðnir. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.